BACKGROUND: Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia. The recognized human subtypes of PIV are numbered 1-4. This study calculates estimates of PIV-associated hospitalizations among U.S. children younger than 5 years using the latest available data. METHODS: Data from the National Respiratory and Enteric Virus Surveillance System were used to characterize seasonal PIV trends from July 2004 through June 2010. To estimate the number of PIV-associated hospitalizations that occurred annually among U.S. children aged <5 years from 1998 through 2010, respiratory hospitalizations from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample were multiplied by the proportion of acute respiratory infection hospitalizations positive for PIV among young children enrolled in the New Vaccine Surveillance Network. Estimates of hospitalization charges attributable to PIV infection were also calculated. RESULTS: Parainfluenza virus seasonality follows type-specific seasonal patterns, with PIV-1 circulating in odd-numbered years and PIV-2 and -3 circulating annually. The average annual estimates of PIV-associated bronchiolitis, croup, and pneumonia hospitalizations among children aged <5 years in the United States were 3888 (0.2 hospitalizations per 1000), 8481 per year (0.4 per 1000 children), and 10,186 (0.5 per 1000 children), respectively. Annual charges for PIV-associated bronchiolitis, croup, and pneumonia hospitalizations were approximately $43 million, $58 million, and $158 million, respectively. CONCLUSIONS: The majority of PIV-associated hospitalizations in young children occur among those aged 0 to 2 years. When vaccines for PIV become available, immunization would be most effective if realized within the first year of life. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia. The recognized human subtypes of PIV are numbered 1-4. This study calculates estimates of PIV-associated hospitalizations among U.S. children younger than 5 years using the latest available data. METHODS: Data from the National Respiratory and Enteric Virus Surveillance System were used to characterize seasonal PIV trends from July 2004 through June 2010. To estimate the number of PIV-associated hospitalizations that occurred annually among U.S. children aged <5 years from 1998 through 2010, respiratory hospitalizations from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample were multiplied by the proportion of acute respiratory infection hospitalizations positive for PIV among young children enrolled in the New Vaccine Surveillance Network. Estimates of hospitalization charges attributable to PIV infection were also calculated. RESULTS: Parainfluenza virus seasonality follows type-specific seasonal patterns, with PIV-1 circulating in odd-numbered years and PIV-2 and -3 circulating annually. The average annual estimates of PIV-associated bronchiolitis, croup, and pneumonia hospitalizations among children aged <5 years in the United States were 3888 (0.2 hospitalizations per 1000), 8481 per year (0.4 per 1000 children), and 10,186 (0.5 per 1000 children), respectively. Annual charges for PIV-associated bronchiolitis, croup, and pneumonia hospitalizations were approximately $43 million, $58 million, and $158 million, respectively. CONCLUSIONS: The majority of PIV-associated hospitalizations in young children occur among those aged 0 to 2 years. When vaccines for PIV become available, immunization would be most effective if realized within the first year of life. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Alicia M Fry; Aaron T Curns; Kathryn Harbour; Lori Hutwagner; Robert C Holman; Larry J Anderson Journal: Clin Infect Dis Date: 2006-09-13 Impact factor: 9.079
Authors: Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins Journal: Expert Rev Respir Med Date: 2011-08 Impact factor: 3.772
Authors: Roderick S Tang; Richard R Spaete; Mark W Thompson; Mia MacPhail; Jeanne M Guzzetta; Patricia C Ryan; Keith Reisinger; Patricia Chandler; Milo Hilty; Robert E Walker; Margarita M Gomez; Genevieve A Losonsky Journal: Vaccine Date: 2008-09-24 Impact factor: 3.641
Authors: Marika K Iwane; Kathryn M Edwards; Peter G Szilagyi; Frances J Walker; Marie R Griffin; Geoffrey A Weinberg; Charmaine Coulen; Katherine A Poehling; Laura P Shone; Sharon Balter; Caroline B Hall; Dean D Erdman; Karen Wooten; Benjamin Schwartz Journal: Pediatrics Date: 2004-06 Impact factor: 7.124
Authors: Janet A Englund; Ruth A Karron; Coleen K Cunningham; Philip Larussa; Ann Melvin; Ram Yogev; Ed Handelsman; George K Siberry; Bhavanji Thumar; Elizabeth Schappell; Catherine V Bull; Helen Y Chu; Anne Schaap-Nutt; Ursula Buchholz; Peter L Collins; Alexander C Schmidt Journal: Vaccine Date: 2013-10-05 Impact factor: 3.641
Authors: Paibel I Aguayo-Hiraldo; Reuben J Arasaratnam; Ifigeneia Tzannou; Manik Kuvalekar; Premal Lulla; Swati Naik; Caridad A Martinez; Pedro A Piedra; Juan F Vera; Ann M Leen Journal: J Infect Dis Date: 2017-07-15 Impact factor: 5.226
Authors: Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Yaroslav Tsybovsky; Li Ou; Baoshan Zhang; Blanca Fernandez-Rodriguez; Valentina Gilardi; Chiara Silacci-Fregni; Martina Beltramello; Ulrich Baxa; Aliaksandr Druz; Wing-Pui Kong; Paul V Thomas; Yongping Yang; Kathryn E Foulds; John-Paul Todd; Hui Wei; Andres M Salazar; Diana G Scorpio; Bridget Carragher; Clinton S Potter; Davide Corti; John R Mascola; Antonio Lanzavecchia; Peter D Kwong Journal: Proc Natl Acad Sci U S A Date: 2018-11-12 Impact factor: 11.205
Authors: Erik M Contreras; Isaac Abrrey Monreal; Martin Ruvalcaba; Victoria Ortega; Hector C Aguilar Journal: Curr Opin Virol Date: 2021-09-27 Impact factor: 7.090
Authors: Akhil Chellapuri; Matthew Smitheman; Joseph G Chappell; Gemma Clark; Hannah C Howson-Wells; Louise Berry; Jonathan K Ball; William L Irving; Alexander W Tarr; C Patrick McClure Journal: Influenza Other Respir Viruses Date: 2022-06-07 Impact factor: 5.606
Authors: Michael J Norris; Monica L Husby; William B Kiosses; Jieyun Yin; Roopashi Saxena; Linda J Rennick; Anja Heiner; Stephanie S Harkins; Rudramani Pokhrel; Sharon L Schendel; Kathryn M Hastie; Sara Landeras-Bueno; Zhe Li Salie; Benhur Lee; Prem P Chapagain; Andrea Maisner; W Paul Duprex; Robert V Stahelin; Erica Ollmann Saphire Journal: Sci Adv Date: 2022-07-20 Impact factor: 14.957
Authors: Mariana Valério; Diogo A Mendonça; João Morais; Carolina C Buga; Carlos H Cruz; Miguel A R B Castanho; Manuel N Melo; Cláudio M Soares; Ana Salomé Veiga; Diana Lousa Journal: ACS Chem Biol Date: 2022-05-02 Impact factor: 4.634
Authors: Larissa Dirr; Ibrahim M El-Deeb; Leonard M G Chavas; Patrice Guillon; Mark von Itzstein Journal: Sci Rep Date: 2017-07-03 Impact factor: 4.379